Elisa Karhu, Steven E. Atlas, Jinrun Gao, Syed A. Mehdi, Dominique Musselman, Sharon Goldberg, Judi M. Woolger, Raul Corredor, Muhammad H. Abbas, Leopoldo Arosemena, Simone Caccamo, Ashar Farooqi, Janet Konefal, Laura Lantigua, Vanessa Padilla, Ammar Rasul, Eduard Tiozzo, Oscar L. Higuera, Andrea Fiallo, John E. Lewis
Karhu et al., J Clin Transl Res, 2018, 4(1): 2
Published online: April 4, 2018
Abstract
Background: Magnesium (Mg) deficiency contributes to the pathophysiology of numerous diseases, and the therapeutic use of Mg has steadily increased by consumers over time. The increased in-hospital use of intravenous (IV) magnesium sulfate (MgSO4) warrants more extensive study regarding the safety of the therapy. The aim of this study was to determine the safety of IV MgSO4 infusion on cardiovascular, liver, kidney, and metabolic markers in adults.
Methods: Twelve volunteers were randomized to one of two conditions: (a) IV infusion of MgSO4 in 5% dextrose followed by IV infusion of 5% dextrose 1 week later or (b) IV infusion of 5% dextrose followed by IV infusion of MgSO4 in 5% dextrose 1 week later. An electrocardiogram was monitored continuously throughout the course of the infusions. Blood was drawn pre- and post-infusions for complete blood count/chemistry, high-density lipoprotein and low-density lipoprotein cholesterol, and triglycerides.
Results: Serum Mg increased from pre- to post-infusion in the MgSO4 + 5% dextrose group (p<0.0001). The QRS interval length increased from pre- to post-infusion in the MgSO4 + 5% dextrose group (p<0.04). Additionally, serum glucose concentration increased in the MgSO4 + 5% dextrose group (p = 0.04). These significant findings were modeled with gender and age as covariates. No other significant differences were found.
Conclusions: The administration of IV infusion of MgSO4 (4 g/100 mL) in 5% dextrose over a 4-hour treatment period poses no significant deleterious effects on cardiovascular, liver, kidney, or metabolic function.
Relevance for patients: IV infusion of MgSO4 may be used for proper treatment indications without significant concern for adverse effects on cardiovascular, liver, kidney, or metabolic function.
DOI: http://dx.doi.org/10.18053/jctres.04.201801.002
Author affiliation
Departments of 1 Medicine, 3 Psychiatry and Behavioral Sciences, and 5 Family Medicine and Community Health, University of Miami Miller School of Medicine, Miami, FL, USA; 2 Barclay’s, Inc., Wilmington, DE, USA; 4 Glow Health PA, Bay Harbor Islands, FL, USA.
*Corresponding author:
John E. Lewis
University of Miami Miller School of Medicine, Department of Psychiatry & Behavioral Sciences, 1120 NW 14th Street, Suite #1482A (D28), Miami, FL 33136 USA
Tel: +1 305 243 6227; Fax: +1 305 243 1619
Email: jelewis@miami.edu
Handling editor
Michal Heger
Department of Experimental Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
Downloads
Full text PDF
